MichaelWMethodMDMPH, MBA

Oncology • Indianapolis, IN

Cancer Genetics/Cancer Risk Assessment, Gynecologic Cancer, Hospice & Palliative

Associate Professor, Indiana University School of Medical Director, Division of Gynecologic Oncology

Join to view full profile

Dr. Method is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Method's full profile

Already have an account?

Office
7979 N Shadeland Ave
Ste 310
Indianapolis, IN 46250
Phone+1 317-621-3780

Fax+1 317-621-3088

Education & Training

University of Notre DameMBA, 2007 - 2009
University of Miami/Jackson Health SystemFellowship, Gynecologic Oncology, 1993 - 1996
University of California (San Francisco)Residency, Obstetrics and Gynecology, 1986 - 1990
Northwestern McGaw/CMH1983 - 1986
University of Notre DameBS, Biochemistry, High Honors, 1982 - 1986
Northwestern University The Feinberg School of MedicineClass of 1986, MD

Certifications & Licensure

IN State Medical License 1998 - 2025
MI State Medical License 1999 - 2022
MS State Medical License 1997 - 2019
AL State Medical License 1997 - 2018
FL State Medical License 1991 - 1998
IL State Medical License 1989 - 1990

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Acute Pain Caused by Paclitaxel in Patients With Cancer Start of enrollment: 2009 Feb 01
Completed
Home-Based Programs for Improving Sleep in Cancer Survivors Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Start of enrollment: 2010 Dec 01
Completed
Phase 3
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy Start of enrollment: 2011 Apr 01
Completed
Phase 3
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Start of enrollment: 2011 Jul 01
Completed
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Start of enrollment: 2012 Jun 15
Completed
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

22 citations
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.
Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown
Future Oncology. 2022-07-01
2 citations
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch
BMC Cancer. 2022-05-06
10 citations
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies...
Monika D Polewski, Gitte B Nielsen, Ying Gu, Aaron T Weaver, Gavin Gegg
Applied Immunohistochemistry & Molecular Morphology. 2022-04-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society for Radiation Oncology - ASTRO
Member
Society of Gynecologic Oncology
Fellow
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member